CD274 and non-small cell lung carcinoma: Several previous US-based studies have evaluated the cost-effectiveness of pembrolizumab or atezolizumab versus platinum-based chemotherapy in the first-line setting of advanced NSCLC patients with PD-L1 of at least 50% (Huang et al., 2017; Peng et al., 2021).